{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/multiple-myeloma/diagnosis/when-should-i-suspect-multiple-myeloma/","result":{"pageContext":{"chapter":{"id":"d1d186e7-f167-55b0-a9ba-20bc6df07ce9","slug":"when-should-i-suspect-multiple-myeloma","fullItemName":"When should I suspect multiple myeloma?","depth":2,"htmlHeader":"<!-- begin field ae7df392-96c2-4c6d-bc07-078ba59c6d8c --><h2>When should I suspect multiple myeloma?</h2><!-- end field ae7df392-96c2-4c6d-bc07-078ba59c6d8c -->","summary":"","htmlStringContent":"<!-- begin item f9d20b3b-51df-41dd-bada-f21dd7a95453 --><!-- begin field 40635353-344a-4e0d-b622-25e7bd81e9af --><ul><li><strong>Multiple myeloma may present with non-specific symptoms.</strong></li><li><strong>Suspect multiple myeloma in adults, particularly over 60 years of age with:</strong><ul><li>Unexplained bone pain (often in the lower back or thoracic area).<ul><li>Present in up to 60–70% of people and may have pre-existed for months.</li></ul></li><li>Fatigue — present in about 30% of people.</li><li>Symptoms of hypercalcaemia (such as bone pain, abdominal pain, depression, confusion, muscle weakness, constipation, thirst, and polyuria) — present in up to 30% of people.<ul><li>For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/hypercalcaemia/\">Hypercalcaemia</a>.</li></ul></li><li>Weight loss — present in about 25% of people.</li><li>Symptoms related to hyperviscosity such as headache, visual disturbance, cognitive impairment, breathlessness, or mucosal bleeding — present in less than 7% of people.</li><li>Symptoms of spinal cord compression (such as sensory loss, paraesthesiae, limb weakness, difficulty walking, sphincter disturbance, and spinal deformity) — present in about 5% of people.</li><li>Fever — present in less than 1% of people.</li></ul></li><li><strong>Multiple myeloma may present with other complications such as pathological fractures and recurrent infection.</strong></li><li><strong>Examination may be normal. In some people, there may be:</strong><ul><li>Hepatomegaly — present in about 4% of people.</li><li>Splenomegaly — present in about 1% of people.</li><li>Lymphadenopathy — present in about 1% of people.</li></ul></li><li><strong>Occasionally, multiple myeloma can be asymptomatic (or 'smouldering') and is identified from incidental findings on blood tests, such as:</strong><ul><li>Normochromic, normocytic anaemia — present in up to 70% of people.</li><li>Renal impairment — present in about 50% of people.</li><li>Hypercalcaemia — present in about 15% of people.</li><li>Raised erythrocyte sedimentation rate (ESR), plasma viscosity, serum protein, or globulin.</li></ul></li></ul><!-- end field 40635353-344a-4e0d-b622-25e7bd81e9af --><!-- end item f9d20b3b-51df-41dd-bada-f21dd7a95453 -->","topic":{"id":"a3257bde-777f-5b48-80cd-28a6de5401b7","topicId":"d449062b-fe98-40a2-bc4d-741f0b91c31d","topicName":"Multiple myeloma","slug":"multiple-myeloma","lastRevised":"Last revised in January 2021","chapters":[{"id":"001bce70-f61f-5905-b9a0-76e49dc2928b","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"a4e4ac31-e5c3-5d0d-ba8e-e28d748b38a8","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"d731856b-56b9-5d81-9db1-6e0380152383","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"288251ee-9e56-550b-bb07-75c191dd88bb","slug":"changes","fullItemName":"Changes"},{"id":"972750f6-1493-51ac-bb67-61a883caef31","slug":"update","fullItemName":"Update"}]},{"id":"9ee3d2ca-5de2-5a81-be8d-5389cb6b96fb","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"02fc2e8c-0154-52e2-81b7-13f9f7ae4157","slug":"goals","fullItemName":"Goals"},{"id":"297bf476-1f3c-5477-859b-fc44c3d58cdd","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"ca441620-7e21-5b08-9340-cca6210d21e9","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"23d46a0d-5d23-5d38-a2d7-817babead45a","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"7f4644ec-a108-52f6-874b-8644bd8da047","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"c6fdac6a-e178-59a4-bcb7-a22337d627a4","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"c45f4611-e831-51b1-ae27-0421b247f510","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"7e70c907-9e94-5f79-b9bb-ba6799a19ccd","slug":"definition","fullItemName":"Definition"},{"id":"64fa3b9a-e0f1-5f2c-aa6b-99ca7f657bb9","slug":"prevalence","fullItemName":"Prevalence"},{"id":"222268d1-82ef-5947-9a94-81c9475bd101","slug":"risk-factors","fullItemName":"Risk Factors"},{"id":"f2cd915a-2200-5a59-9f4b-e92d4e9721d6","slug":"prognosis","fullItemName":"Prognosis"},{"id":"b84e32aa-3d7d-5e4b-a3d8-9c8cc506b4a9","slug":"complications","fullItemName":"Complications"}]},{"id":"cd2396e2-8290-5f66-ad0f-871bfebc83dd","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"d1d186e7-f167-55b0-a9ba-20bc6df07ce9","slug":"when-should-i-suspect-multiple-myeloma","fullItemName":"When should I suspect multiple myeloma?"},{"id":"8116b468-694e-5fa4-aa60-09f23bc088e0","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"46717c89-6886-52dc-8e80-d8fb592c32b2","fullItemName":"Management","slug":"management","subChapters":[{"id":"da1a6baa-3eff-5249-bb76-6d086063c369","slug":"suspected-multiple-myeloma","fullItemName":"Scenario: Suspected multiple myeloma"},{"id":"c51edfd3-b143-5dfe-b734-2f46b572a5de","slug":"confirmed-multiple-myeloma","fullItemName":"Scenario: Confirmed multiple myeloma"},{"id":"1544f647-8ce2-51e4-adee-9cb61fc46ae1","slug":"end-stage-multiple-myeloma","fullItemName":"Scenario: End-stage multiple myeloma"}]},{"id":"375c8b98-56b6-5c85-a182-36856a3db2ca","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"b088260f-8cf4-5102-b99d-ab78d3ac71d3","slug":"analgesia","fullItemName":"Analgesia"}]},{"id":"ddabb890-df48-5057-a56f-32666fa74e9a","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"9764188e-1795-5b4f-8cdf-b70befc3fe0d","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"aef9e65b-4f13-546f-adbc-19654498aa31","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"79a1401a-ca39-5eff-ab8b-482281e9741f","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"b84ca8eb-2866-56cb-b7a1-ecb59575fddc","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"592f1670-1381-587b-baec-8618a8caf851","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"e6e2cada-c7c4-5f01-bf87-9cecee0c53f0","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"6b485c3d-36d7-556a-993b-3311a38b7bf6","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"cd2396e2-8290-5f66-ad0f-871bfebc83dd","slug":"diagnosis","fullItemName":"Diagnosis"},"subChapters":[{"id":"d879416c-e0ec-57cd-9f08-a1b278668dbc","slug":"basis-for-recommendation-d0e","fullItemName":"Basis for recommendation","depth":3,"htmlHeader":"<!-- begin field 6313a11a-c2fa-47b8-af7c-303f0dadbca2 --><h3>Basis for recommendation</h3><!-- end field 6313a11a-c2fa-47b8-af7c-303f0dadbca2 -->","summary":null,"htmlStringContent":"<!-- begin item d0ed4ef1-6e8a-428a-9ea8-e4fcc8772098 --><!-- begin field fac02bc1-bdc8-4e4d-af3b-745df8b5cccf --><p>The information on when to suspect multiple myeloma is based on the NICE clinical guideline <em>Suspected cancer - recognition and referral</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-myeloma/references/\">NICE, 2015a</a>], the<em> International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-myeloma/references/\">Rajkumar, 2014</a>], and expert opinion in review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-myeloma/references/\">Shephard, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-myeloma/references/\">Goldschmidt, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-myeloma/references/\">Ramsenthaler, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-myeloma/references/\">Yong, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-myeloma/references/\">BMJ Best Practice, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-myeloma/references/\">Bird, 2019</a>] and from Cancer Research UK [<a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-myeloma/references/\">CRUK, 2020</a>].</p><!-- end field fac02bc1-bdc8-4e4d-af3b-745df8b5cccf --><!-- end item d0ed4ef1-6e8a-428a-9ea8-e4fcc8772098 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}